Anti-VEEV antibodies and their use in prophylaxis or treatment

The invention relates to a polypeptide comprising a humanised antibody or a fragment thereof, wherein the said antibody comprises at least one CDR selected from SEQ ID Nos: 3, 4 5, 6, 7 or 8 or a modified form of any of these, and binds Venezuelan equine encephalitis virus (VEEV) for use in the prop...

Full description

Saved in:
Bibliographic Details
Main Authors ROBERT JOHN PHILLPOTTS, STUART DAVID PERKINS, LYN MARGARET O'BRIEN, SARAH ANN GOODCHILD
Format Patent
LanguageEnglish
Published 29.05.2013
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The invention relates to a polypeptide comprising a humanised antibody or a fragment thereof, wherein the said antibody comprises at least one CDR selected from SEQ ID Nos: 3, 4 5, 6, 7 or 8 or a modified form of any of these, and binds Venezuelan equine encephalitis virus (VEEV) for use in the prophylaxis or treatment of VEEV or Mucambo virus infection in humans, wherein the polypeptide is for administration more than 24 hours and less than 65 hours post-exposure to the virus. Also claimed is a combination of such a polypeptide with a second polypeptide that comprises an anti-VEEV antibody or fragment thereof that binds a different epitope of VEEV; a pharmaceutical composition comprising the same, and methods for preventing or treating a VEEV or Mucambo infection. The antibody may bind the E2h epitope within the E2 glycoprotein of VEEV.
Bibliography:Application Number: GB20110020096